Imatinib and pegylated IFN-alfa2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150373" target="_blank" >RIV/61989592:15110/14:33150373 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ejh.12258" target="_blank" >http://dx.doi.org/10.1111/ejh.12258</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ejh.12258" target="_blank" >10.1111/ejh.12258</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Imatinib and pegylated IFN-alfa2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Popis výsledku v původním jazyce

OBJECTIVES: Previous studies indicate that 40-50% of patients with chronic myeloid leukemia in prolonged complete molecular remission may discontinue imatinib therapy without imminent relapse. The combination of pegylated interferon-alpha (Peg-IFN-alfa2b) and imatinib may increase the rate of successful discontinuation. METHODS: In this pilot study, we prospectively stopped imatinib from patients (n = 12) who had achieved major molecular response (MMR) after ?12 months of treatment with either imatinibor imatinib+Peg-IFN-alfa2b. Molecular monitoring was carried out monthly for BCR-ABL1. In addition, analyses of lymphocyte immunophenotype, function, and plasma cytokines were performed. RESULTS: In the monotherapy group, 5/6 patients lost MMR within 4 months. One patient remains to date in MR(4.0) 61 months after discontinuation. In the combination therapy group, 2/6 patients relapsed within 4 months while still receiving Peg-IFN-alfa2b. Four of six patients were able to discontinue bot

Název v anglickém jazyce

Imatinib and pegylated IFN-alfa2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Popis výsledku anglicky

OBJECTIVES: Previous studies indicate that 40-50% of patients with chronic myeloid leukemia in prolonged complete molecular remission may discontinue imatinib therapy without imminent relapse. The combination of pegylated interferon-alpha (Peg-IFN-alfa2b) and imatinib may increase the rate of successful discontinuation. METHODS: In this pilot study, we prospectively stopped imatinib from patients (n = 12) who had achieved major molecular response (MMR) after ?12 months of treatment with either imatinibor imatinib+Peg-IFN-alfa2b. Molecular monitoring was carried out monthly for BCR-ABL1. In addition, analyses of lymphocyte immunophenotype, function, and plasma cytokines were performed. RESULTS: In the monotherapy group, 5/6 patients lost MMR within 4 months. One patient remains to date in MR(4.0) 61 months after discontinuation. In the combination therapy group, 2/6 patients relapsed within 4 months while still receiving Peg-IFN-alfa2b. Four of six patients were able to discontinue bot

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12218" target="_blank" >NT12218: Individualizovaná léčba chronických myeloproliferativních stavů a myelodysplastického syndromu - studie buněčné metabolomiky</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Haematology

ISSN

0902-4441

e-ISSN

—

Svazek periodika

92

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

413-420

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—